Skip to main content
Erschienen in: Journal of Neurology 3/2022

18.07.2021 | Original Communication

Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis

verfasst von: Ji He, Jiayu Fu, Wei Zhao, Chuan Ren, Ping Liu, Lu Chen, Dan Li, Lu Tang, Lequn Zhou, Yixuan Zhang, Xinran Ma, Gaoqi Zhang, Nan Li, Dongsheng Fan

Erschienen in: Journal of Neurology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

Exploration of hypermetabolism in amyotrophic lateral sclerosis (ALS) with different ethnicities is needed to understand its metabolic implications for clinical management. We aimed to evaluate the features of hypermetabolism and investigate its association with clinical characteristics and prognosis of ALS in a prospective Chinese cohort.

Methods

This prospective study was conducted at Peking University Third Hospital, China from 2017 to 2020. 343 participants were enrolled initially. After strict screening, 147 matched health controls and 93 patients with ALS were eligible and underwent detailed clinical assessments. Disease severity and progression were evaluated using recognized scales. Metabolic assessments included body composition and metabolic index (MI) [hypermetabolism if MI ≥ 120.0%]. Patients were followed up every 6 months for survival analysis.

Results

Compared with controls, hypermetabolism was significantly more prevalent in ALS (p = 0.009). MI was consistently higher in ALS than controls (p = 0.009). Further correlation analysis showed that MI significantly decreased with disease progression, as graded by King’s College staging system (p < 0.001). MI was significantly correlated with fat-free mass and fat mass (p = 0.005 and 0.007). Survival analysis showed that hypermetabolism independently indicated a worse prognosis for ALS (HR = 1.020, CI = 1.004–1.036, p = 0.013).

Conclusion

A significant increase in the prevalence and degree of hypermetabolism was identified in ALS compared with strictly matched controls. Metabolic index, which is significantly associated with disease progression and body composition, is an independent prognostic indicator for a worse survival of ALS.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat van Es MA, Hardiman O, Chio A et al (2017) Amyotrophic lateral sclerosis. Lancet 390(10107):2084–2098PubMedCrossRef van Es MA, Hardiman O, Chio A et al (2017) Amyotrophic lateral sclerosis. Lancet 390(10107):2084–2098PubMedCrossRef
2.
Zurück zum Zitat Nolano M, Provitera V, Manganelli F et al (2017) Non-motor involvement in amyotrophic lateral sclerosis: new insight from nerve and vessel analysis in skin biopsy. Neuropathol Appl Neurobiol 43(2):119–132PubMedCrossRef Nolano M, Provitera V, Manganelli F et al (2017) Non-motor involvement in amyotrophic lateral sclerosis: new insight from nerve and vessel analysis in skin biopsy. Neuropathol Appl Neurobiol 43(2):119–132PubMedCrossRef
3.
Zurück zum Zitat Chen L, Zhang B, Chen R et al (2015) Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry 86(10):1075–1081PubMedCrossRef Chen L, Zhang B, Chen R et al (2015) Natural history and clinical features of sporadic amyotrophic lateral sclerosis in China. J Neurol Neurosurg Psychiatry 86(10):1075–1081PubMedCrossRef
4.
Zurück zum Zitat Shahrizaila N, Sobue G, Kuwabara S et al (2016) Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry 87(8):821–830PubMedCrossRef Shahrizaila N, Sobue G, Kuwabara S et al (2016) Amyotrophic lateral sclerosis and motor neuron syndromes in Asia. J Neurol Neurosurg Psychiatry 87(8):821–830PubMedCrossRef
5.
Zurück zum Zitat Dupuis L, Pradat PF, Ludolph AC, Loeffler JP (2011) Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 10(1):75–82PubMedCrossRef Dupuis L, Pradat PF, Ludolph AC, Loeffler JP (2011) Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol 10(1):75–82PubMedCrossRef
6.
Zurück zum Zitat Crugnola V, Lamperti C, Lucchini V et al (2010) Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch Neurol 67(7):849–854PubMedCrossRef Crugnola V, Lamperti C, Lucchini V et al (2010) Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch Neurol 67(7):849–854PubMedCrossRef
7.
Zurück zum Zitat Steyn FJ, Ioannides ZA, van Eijk RPA et al (2018) Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry 89(10):1016–1023PubMedCrossRef Steyn FJ, Ioannides ZA, van Eijk RPA et al (2018) Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J Neurol Neurosurg Psychiatry 89(10):1016–1023PubMedCrossRef
8.
9.
Zurück zum Zitat Desport JC, Preux PM, Magy L et al (2001) Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 74(3):328–334PubMedCrossRef Desport JC, Preux PM, Magy L et al (2001) Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 74(3):328–334PubMedCrossRef
10.
Zurück zum Zitat Desport JC, Torny F, Lacoste M, Preux PM, Couratier P (2005) Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2(3–4):202–207PubMedCrossRef Desport JC, Torny F, Lacoste M, Preux PM, Couratier P (2005) Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. Neurodegener Dis 2(3–4):202–207PubMedCrossRef
11.
Zurück zum Zitat Bouteloup C, Desport JC, Clavelou P et al (2009) Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol 256(8):1236–1242PubMedCrossRef Bouteloup C, Desport JC, Clavelou P et al (2009) Hypermetabolism in ALS patients: an early and persistent phenomenon. J Neurol 256(8):1236–1242PubMedCrossRef
12.
Zurück zum Zitat Wills AM, Hubbard J, Macklin EA et al (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 383(9934):2065–2072PubMedPubMedCentralCrossRef Wills AM, Hubbard J, Macklin EA et al (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet 383(9934):2065–2072PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Ludolph AC, Dorst J, Dreyhaupt J et al (2020) Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol 87(2):206–216PubMedCrossRef Ludolph AC, Dorst J, Dreyhaupt J et al (2020) Effect of high-caloric nutrition on survival in amyotrophic lateral sclerosis. Ann Neurol 87(2):206–216PubMedCrossRef
14.
Zurück zum Zitat Brand D, Polak M, Glass JD, Fournier CN (2021) Comparison of phenotypic characteristics and prognosis between black and white patients in a tertiary ALS clinic. Neurology 96(6):e840–e844PubMedCrossRef Brand D, Polak M, Glass JD, Fournier CN (2021) Comparison of phenotypic characteristics and prognosis between black and white patients in a tertiary ALS clinic. Neurology 96(6):e840–e844PubMedCrossRef
15.
Zurück zum Zitat He J, Fu JY, Chen L et al (2020) Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol. BMJ Open 10(12):e042603PubMedPubMedCentralCrossRef He J, Fu JY, Chen L et al (2020) Multicentre, prospective registry study of amyotrophic lateral sclerosis in mainland China (CHALSR): study protocol. BMJ Open 10(12):e042603PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Gordon PH, Cheung YK (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 67(7):1314–1315PubMedCrossRef Gordon PH, Cheung YK (2006) Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology 67(7):1314–1315PubMedCrossRef
17.
Zurück zum Zitat Lechtzin N, Cudkowicz ME, de Carvalho M et al (2018) Respiratory measures in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 19(5–6):321–330PubMedCrossRef Lechtzin N, Cudkowicz ME, de Carvalho M et al (2018) Respiratory measures in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 19(5–6):321–330PubMedCrossRef
18.
Zurück zum Zitat Ravits J, Paul P, Jorg C (2007) Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 68(19):1571–1575PubMedCrossRef Ravits J, Paul P, Jorg C (2007) Focality of upper and lower motor neuron degeneration at the clinical onset of ALS. Neurology 68(19):1571–1575PubMedCrossRef
19.
20.
Zurück zum Zitat Benatar M, Zhang L, Wang L et al (2020) Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95(1):e59–e69PubMedPubMedCentralCrossRef Benatar M, Zhang L, Wang L et al (2020) Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS. Neurology 95(1):e59–e69PubMedPubMedCentralCrossRef
22.
Zurück zum Zitat Miller WM, Spring TJ, Zalesin KC et al (2012) Lower than predicted resting metabolic rate is associated with severely impaired cardiorespiratory fitness in obese individuals. Obesity (Silver Spring) 20(3):505–511CrossRef Miller WM, Spring TJ, Zalesin KC et al (2012) Lower than predicted resting metabolic rate is associated with severely impaired cardiorespiratory fitness in obese individuals. Obesity (Silver Spring) 20(3):505–511CrossRef
24.
Zurück zum Zitat Ellis AC, Rosenfeld J (2011) Which equation best predicts energy expenditure in amyotrophic lateral sclerosis? J Am Diet Assoc 111(11):1680–1687PubMedCrossRef Ellis AC, Rosenfeld J (2011) Which equation best predicts energy expenditure in amyotrophic lateral sclerosis? J Am Diet Assoc 111(11):1680–1687PubMedCrossRef
25.
Zurück zum Zitat Jésus P, Fayemendy P, Nicol M et al (2018) Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol 25(1):97–104PubMedCrossRef Jésus P, Fayemendy P, Nicol M et al (2018) Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur J Neurol 25(1):97–104PubMedCrossRef
26.
Zurück zum Zitat Sherman MS, Pillai A, Jackson A, Heiman-Patterson T (2004) Standard equations are not accurate in assessing resting energy expenditure in patients with amyotrophic lateral sclerosis. JPEN J Parenter Enteral Nutr 28(6):442–446PubMedCrossRef Sherman MS, Pillai A, Jackson A, Heiman-Patterson T (2004) Standard equations are not accurate in assessing resting energy expenditure in patients with amyotrophic lateral sclerosis. JPEN J Parenter Enteral Nutr 28(6):442–446PubMedCrossRef
27.
Zurück zum Zitat Vaisman N, Lusaus M, Nefussy B et al (2009) Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Sci 279(1–2):26–29PubMedCrossRef Vaisman N, Lusaus M, Nefussy B et al (2009) Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? J Neurol Sci 279(1–2):26–29PubMedCrossRef
28.
Zurück zum Zitat Funalot B, Desport JC, Sturtz F, Camu W, Couratier P (2009) High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10(2):113–117PubMedCrossRef Funalot B, Desport JC, Sturtz F, Camu W, Couratier P (2009) High metabolic level in patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 10(2):113–117PubMedCrossRef
29.
Zurück zum Zitat Georges M, Morélot-Panzini C, Similowski T, Gonzalez-Bermejo J (2014) Noninvasive ventilation reduces energy expenditure in amyotrophic lateral sclerosis. BMC Pulm Med 14:17PubMedPubMedCentralCrossRef Georges M, Morélot-Panzini C, Similowski T, Gonzalez-Bermejo J (2014) Noninvasive ventilation reduces energy expenditure in amyotrophic lateral sclerosis. BMC Pulm Med 14:17PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Ahmed RM, Ke YD, Vucic S et al (2018) Physiological changes in neurodegeneration - mechanistic insights and clinical utility. Nat Rev Neurol 14(5):259–271PubMedCrossRef Ahmed RM, Ke YD, Vucic S et al (2018) Physiological changes in neurodegeneration - mechanistic insights and clinical utility. Nat Rev Neurol 14(5):259–271PubMedCrossRef
31.
Zurück zum Zitat Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ (1996) Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr 63(1):130–137PubMedCrossRef Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ (1996) Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr 63(1):130–137PubMedCrossRef
32.
Zurück zum Zitat Marin B, Desport JC, Kajeu P et al (2011) Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 82(6):628–634PubMedCrossRef Marin B, Desport JC, Kajeu P et al (2011) Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry 82(6):628–634PubMedCrossRef
33.
Zurück zum Zitat Dupuis L, Oudart H, René F, de Aguilar JLG, Loeffler JP (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA 101(30):11159–11164PubMedPubMedCentralCrossRef Dupuis L, Oudart H, René F, de Aguilar JLG, Loeffler JP (2004) Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA 101(30):11159–11164PubMedPubMedCentralCrossRef
34.
Zurück zum Zitat De Vocht J, Blommaert J, Devrome M et al (2020) Use of multimodal imaging and clinical biomarkers in presymptomatic carriers of C9orf72 repeat expansion. JAMA Neurol 77(8):1008–1017PubMedCrossRef De Vocht J, Blommaert J, Devrome M et al (2020) Use of multimodal imaging and clinical biomarkers in presymptomatic carriers of C9orf72 repeat expansion. JAMA Neurol 77(8):1008–1017PubMedCrossRef
35.
Zurück zum Zitat Ioannides ZA, Ngo ST, Henderson RD, McCombe PA, Steyn FJ (2016) Altered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progression. Neurodegener Dis 16(5–6):382–397PubMedCrossRef Ioannides ZA, Ngo ST, Henderson RD, McCombe PA, Steyn FJ (2016) Altered metabolic homeostasis in amyotrophic lateral sclerosis: mechanisms of energy imbalance and contribution to disease progression. Neurodegener Dis 16(5–6):382–397PubMedCrossRef
36.
Zurück zum Zitat Al-Sarraj S, King A, Cleveland M et al (2014) Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study. Acta Neuropathol Commun 2:165PubMedPubMedCentralCrossRef Al-Sarraj S, King A, Cleveland M et al (2014) Mitochondrial abnormalities and low grade inflammation are present in the skeletal muscle of a minority of patients with amyotrophic lateral sclerosis; an observational myopathology study. Acta Neuropathol Commun 2:165PubMedPubMedCentralCrossRef
37.
Zurück zum Zitat Jeon GS, Im W, Shim YM et al (2016) Neuroprotective effect of human adipose stem cell-derived extract in amyotrophic lateral sclerosis. Neurochem Res 41(4):913–923PubMedCrossRef Jeon GS, Im W, Shim YM et al (2016) Neuroprotective effect of human adipose stem cell-derived extract in amyotrophic lateral sclerosis. Neurochem Res 41(4):913–923PubMedCrossRef
38.
Zurück zum Zitat Lu CH, Macdonald-Wallis C, Gray E et al (2015) Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84(22):2247–2257PubMedPubMedCentralCrossRef Lu CH, Macdonald-Wallis C, Gray E et al (2015) Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84(22):2247–2257PubMedPubMedCentralCrossRef
39.
40.
Zurück zum Zitat Liu MS, Cui LY, Fan DS (2014) Age at onset of amyotrophic lateral sclerosis in China. Acta Neurol Scand 129(3):163–167PubMedCrossRef Liu MS, Cui LY, Fan DS (2014) Age at onset of amyotrophic lateral sclerosis in China. Acta Neurol Scand 129(3):163–167PubMedCrossRef
41.
Zurück zum Zitat Xu L, Chen L, Wang S et al (2020) Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry 91(5):520–525PubMedCrossRef Xu L, Chen L, Wang S et al (2020) Incidence and prevalence of amyotrophic lateral sclerosis in urban China: a national population-based study. J Neurol Neurosurg Psychiatry 91(5):520–525PubMedCrossRef
Metadaten
Titel
Hypermetabolism associated with worse prognosis of amyotrophic lateral sclerosis
verfasst von
Ji He
Jiayu Fu
Wei Zhao
Chuan Ren
Ping Liu
Lu Chen
Dan Li
Lu Tang
Lequn Zhou
Yixuan Zhang
Xinran Ma
Gaoqi Zhang
Nan Li
Dongsheng Fan
Publikationsdatum
18.07.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 3/2022
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-021-10716-1

Weitere Artikel der Ausgabe 3/2022

Journal of Neurology 3/2022 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.